On 7 September 2026, UNISOUND (09678.HK) voluntarily announced progress in its medical intelligence business, having recently won multiple benchmark smart healthcare projects, including large-model projects at leading Class 3A hospitals, an intelligent fund supervision project for a leading insurance institution and a regional medical intelligence construction project, with a combined contract value of nearly RMB 100 million. The projects are based on vertical large models trained on the company's proprietary foundational model U2, covering in-hospital diagnosis and treatment, fund supervision and regional data governance.
On 7 September, Hong Kong's three major indices came under pressure: the Hang Seng Index fell 0.93% to close at 25,413.12 points and the Hang Seng TECH Index fell 0.92%, with turnover of HK$ 209.673 billion. The Stock Connect eligible list was formally adjusted today, with 54 securities added and 15 removed; Baidu was formally included in Stock Connect, and Citi expects about HK$ 47 billion of incremental inflows over the next 2 to 4 months. On the trading front, optical communication, PCB and other computing-power hardware chains led gains, with CIG up over 24% and ZJ INNOLIGHT up nearly 20%; Chinese banking H-shares broadly corrected and AI application and heavyweight technology stocks weakened. Southbound capital recorded net buying of HK$ 1.275 billion.
On 7 September 2026, The Stock Exchange of Hong Kong Limited announced that the listing status of WISDOM WEALTH (00007.HK) would be cancelled with effect from 9:00 a.m. on 9 September 2026 under Rule 6.01A(1) of the Listing Rules. The company's shares have been suspended since 2 April 2024, and it failed to resume trading on or before 1 October 2025, leading to two delisting decisions by the Listing Committee and an upholding review decision by the Listing Review Committee on 27 August 2026.
September 7, 2026—the three major Hong Kong indices collectively retreated, with the Hang Seng Index down 0.93%, the Hang Seng TECH Index down 0.92%, and the Hang Seng China Enterprises Index down 1.46%. The Hang Seng Index's total market turnover was HK$209.7 billion, Southbound funds saw a net inflow of HK$1.275 billion.
On 7 September 2026, Korea and Asian semiconductor themes in HK shares ETFs broke out broadly. The CSOP KOSPI 200 ETF (3121.HK) rose 5.39% and the Xtrackers MSCI Korea UCITS ETF (2848.HK) rose 5.17%, while the E Fund (HK) Solactive Global Gold Miner Select Index ETF (2824.HK) fell 2.51% and biotech and high-dividend ETFs broadly retreated. NewTimeSpace tracking shows a clear rotation pattern of regional technology breaking out while defensive products came under pressure.
On 7 September 2026, communication and growth themes in Shanghai-Shenzhen Stock Connect ETFs broke out broadly. The Yinhua CSI 5G Communication Theme ETF (159994.SZ) rose 6.36% and the ChinaAMC CSI 5G Communication Theme ETF (515050.SH) rose 6.28%, while the ChinaAMC CSI Shanghai-Shenzhen-Hong Kong Gold Industry Commodity ETF (159562.SZ) fell 2.25% and coal and financial ETFs broadly retreated. NewTimeSpace tracking shows a clear rotation pattern of communication and growth breaking out while resource and value names came under pressure.
The Shanghai and Shenzhen exchanges have simultaneously adjusted the southbound Stock Connect eligible list, effective from September 7, with 54 stocks added (including MANYCORE TECH, BIDU-SW, HENLIUS and HARBIN ELECTRIC) and 15 removed (including MING YUAN CLOUD, NISSIN FOODS and YIDU TECH).
On 6 September 2026, FORMS SYNTRON(300468.SZ) passed the HKEX hearing, with CMB International and Guosen Securities (Hong Kong) as joint sponsors; the Company is a Greater Bay Area-based banking fintech service provider spanning fintech software development, consulting and system integration, with proprietary platforms FINNOSafe and FINNOSmart; it recorded 2025 revenue of RMB 631.1 million with gross margin rising to 37.8% and profit of RMB 74.3 million.
on September 7, 2026, the chip theme rebounded across the board, with SMIC (00981.HK) fluctuating stronger. As of 13:39, the company's quote stood at HKD 69.050, up 2.75%.
on September 7, 2026, the robotics theme strengthened, with UBTECH ROBOTICS (09880.HK) fluctuating higher. As of 13:25, the company's quote stood at HKD 87.200, up 1.81%.
On 7 September 2026, BIDU-SW (09888.HK) announced that its Class A ordinary shares have been included as eligible securities under the Shenzhen-Hong Kong Stock Connect effective the same date (following their inclusion under the Shanghai-Hong Kong Stock Connect announced on 4 September), marking an important step in expanding to Mainland China investors.
On 7 September 2026, TONGGUAN GOLD (00340.HK) announced that, pursuant to notices published by the Shanghai and Shenzhen stock exchanges, its shares have been included in the securities lists under Stock Connect effective the same date.
as of 10:19 on September 7, 2026, the CSI Semiconductor Material Equipment Theme Index (931743) surged 3.50%, with the GF CSI Semiconductor Material Equipment Theme ETF (560780) last quoted at RMB 1. In terms of scale, the ETF's AUM grew by RMB 337 million over the past month, representing significant growth.In terms of shares, the ETF's latest shares outstanding reached 13.066 billion units, hitting a new high over the past year.
as of 10:14 on September 7, 2026, the CSI 5G Communication Theme Index (931079) surged 4.22%, with the ChinaAMC CSI 5G Communication Theme ETF (515050) last quoted at RMB 1.03.In terms of scale, the ETF's latest AUM reached RMB 17.293 billion.In terms of shares, the ETF's latest shares outstanding reached 17.517 billion units, hitting a new high over the past month.
On 7 September 2026, HBM HOLDINGS-B (02142.HK) announced that its shares have been added to the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect lists, effective 7 September 2026, enabling direct investment by qualified mainland Chinese investors through the Stock Connect mechanism.
On 7 September 2026, TENNOR THERAP-B (06872.HK) reported positive Phase IIa proof-of-concept data for rifaquizalone (TNP-2092) in prosthetic joint infection. Based on these data, a multicenter Phase IIb trial has been approved by the NMPA and recently initiated.
